Vanda Pharmaceuticals’ stock dropped significantly following a report of a $220 million loss. Additionally, the D.C. biotech company filed a shelf registration statement for $200 million, indicating plans to raise capital in the coming years. This financial news has led to investor concern, as reflected in the stock’s tumble.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Vanda Pharmaceuticals’ stock tumbles after $220M loss
Vanda Pharmaceuticals’ stock dropped significantly following a report of a $220 million loss. Additionally, the D.C. biotech company filed a shelf registration statement for $200 million, indicating plans to raise capital in the coming years. This financial news has led to investor concern, as reflected in the stock’s tumble.